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Purpose: Problematic polypharmacy can exaggerate “medicine burden” for the patient.
Patient-reported outcomes (PROs) are key indicators of medicine burden, and PRO measures
(PROMs) can help patients articulate their perceptions of medicine burden. We aimed to: (a)
evaluate what PROMs currently exist that assess medicine burden, and what PROs they target,
and (b) understand patients’ experiences with using multiple medicines to establish a core set
of most meaningful and relevant PROs for assessment in polypharmacy medicines reviews.
Patients and Methods:We conducted a prospective, sequential mixed-methods study in two
consecutive work phases. Phase 1 involved a rapid review of PROMs, informed by the
published PRISMA and COSMIN initiative guidelines. We integrated all evidence in
a thematic narrative synthesis. Phase 2 involved cross-sectional, one-to-one, semi-structured
interviews with key stakeholders, including members of the public and healthcare professionals
(HCPs). We conducted thematic content analysis to identify and classify emerging PROs.
Results: In Phase 1, 13 studies described the development and/or validation of 12 PROMs.
The PROMs targeted 14 content domains of adult patients’ experiences with prescribed
medicines. PROMs varied widely in terms of length, comprehensiveness and psychometric
robustness. In Phase 2, all participants (seven members of the public; eight HCPs) agreed on
the clinical relevance of PROMs, providing a rich account of justiﬁcations. We identiﬁed
four core PROs: ‘Knowledge, information and communication about own medicines’;
“Perceptions, views and attitudes about (own) medicines”; “Impact on daily living: Side-
effects and practicalities”, and “Medicine usage: ‘as planned’, misuse, abuse, no use”.
Conclusion: We suggest combining psychometrically robust PROMs or domains across
PROMs into a bespoke PROM that addresses comprehensively and succinctly the four core
PROs. We recommend a careful implementation process that must involve consultation with
all relevant stakeholders, while establishing a clear purpose for collecting a PROM and
realistic and ongoing collection at key time-points.
Keywords: medication experiences, preferences, knowledge, perceptions, impact on daily
living, monitoring
Plain Language Summary
Why Was the Study Done? Patients may ﬁnd taking multiple medicines causes problems
with everyday living. These problems are often called “medicine burden”. One way to get
help for medicine burden is for patients to self-report medicine burden using questionnaires.
These are often called patient-reported outcome measures, or PROMs. In this study, we
wanted to understand: (a) what PROMs are available and how well they have been devel-
oped, and (b) what aspects of medicine burden matter the most.
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What Did the Researchers Do and Find? First, we reviewed
the literature and found 12 PROMs. Then, we interviewed patients,
family members and clinicians. Interviewees felt that PROMs were
well suited to help patients voice their needs. It was agreed that
PROMsmust monitor four areas of medicine burden, ie, (a) knowl-
edge, information and communication about medicines; (b) percep-
tions about (one’s own) medicines; (c) impact on daily living: side-
effects and practicalities, and (d) actual medicine use.. However, no
single PROM fully addressed all four areas.
What Do These Results Mean? To address all of patients’
concerns about medicine burden we suggest combining valid
PROMs into a bespoke PROM that is easy to understand, con-
cise, and includes only the most essential questions.
Introduction
Living with multiple chronic illnesses, or multi-morbidity,1
often demands the use of multiple medicines on a daily
basis.2,3 Polypharmacy is a growing phenomenon
worldwide,4 although often may be clinically warranted.
However, coping with polypharmacy in the presence of
a long-term illness can be challenging for the patient.5
Moreover, “problematic polypharmacy”, ie, multiple medi-
cines prescribed inappropriately, can exaggerate the burden
for the patient.2 This type of burden, known as “medicine
burden”, has been associated with non-adherence, poor clin-
ical outcomes, and diminished patient well-being and satis-
faction with care.6,7 However, medicine burden from the
patient’s viewpoint is still poorly understood, inconsistently
measured and often overlooked.8
Given the extent of multi-morbidity,9 risk for proble-
matic polypharmacy,5 and the numbers of people affected,10
there is an urgent need to measure and understand medicine
burden among people living with multiple chronic illnesses.
Patients’ experiences of using multiple medicines vary
according to number, nature and severity of underlying
chronic illnesses; number of medicines and regimen com-
plexity; route and frequency of administration; medicines
effectiveness and side-effects; and impact on general well-
being.7,11,12
Patient-reported outcomes (PROs) are key indicators of
medicine burden, and PRO measures (or PROMs) can help
patients articulate their own outcomes of care, including
the beneﬁts and risks of prescribed medicines.8,13 PROMs
for polypharmacy medicines reviews can allow for quan-
tiﬁcation of the patient’s perceptions of core outcomes and
medicines-related experiences.14,15 This offers a means to
(a) identify patients at greatest risk of harm, (b) screen
patients for medicine burden, and (c) evaluate the
effectiveness of interventions to tackle problematic poly-
pharmacy and minimise medicine burden.
In Scotland, the Scottish Government’s
Polypharmacy Guidance for Realistic Prescribing16 cen-
tralizes the philosophy “that patients are integral to the
decisions made about their medicines and [must be]
empowered and supported to do so” (p.6) in an attempt
to promote appropriate polypharmacy and medicine
safety. PROMs can play integral role to this direction.
However, before PROMs for polypharmacy medicine
reviews are more widely integrated in clinical practice,
there is a need to: (a) Understand what PROMs cur-
rently exist that assess aspects of medicine burden, and
what PROs they target; (b) Evaluate and synthesize the
evidence on the psychometric properties of existing
PROMs; and (c) Understand patients’ experiences with
using multiple medicines (to identify emerging PROs),
glean views and opinions about the clinical relevance of
PROMs, and establish a core set of PROs viewed as
most meaningful and relevant for polypharmacy medi-
cines reviews. Our study aimed to address the afore-
mentioned knowledge gaps by answering the following
research questions:
RQ1: What PROMs currently exist that assess aspects
of medicine burden, and what PROs do they target?
RQ2: What are the reported psychometric properties of
these PROMs?
RQ3: What are the experiences of patients with using
multiple medicines that can point towards emerging
important PROs?
RQ4: What are the views and opinions of stakeholders
on the clinical use of PROMs to aid polypharmacy med-
icines reviews?
RQ5: Which PROs stakeholders view as the most
meaningful and relevant to be assessed in polypharmacy
medicines reviews?
Materials and Methods
We conducted a prospective, sequential mixed-methods
study that comprised two consecutive work phases, ie,
a rapid literature review (Phase 1) and consultation with
stakeholders (Phase 2).
Rapid Review (Phase 1)
To answer RQs 1 and 2, we carried out a rapid review of
PROMs that target aspects of medicine burden. Our rapid
review was informed by the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
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guidelines17 and conducted according to current guidance
for rapid reviews.18
Search Strategy
A systematic search strategy was developed in consulta-
tion with an academic librarian. Searches were run sepa-
rately in the following databases: MEDLINE (Ovid),
CINAHL (EBSCO), PsycINFO (EBSCO), SocINDEX
(EBSCO), Cochrane Library, Web of Science, and
Google Scholar. The PROQOLID® database (https://epro
vide.mapi-trust.org/) that houses several patient-related
measures was searched for additional articles. Reference
lists of all included articles were examined. Details of the
search terms used for each database can be found in
Supplementary ﬁle 1.
Searches were limited to international research published
in the English language; eligible studies had to be published
between January 1999 and March 2019 to retrieve the most
up-to-date evidence. Database searches were further limited
to studies published between January 2015 and March 2019.
This was because studies published between January 1999
and January 2015 had already been considered in a previous
systematic review8 that identiﬁed 15 PROMs that evaluated
patients’ experiences with medicines. Studies and PROMs
included in that systematic review were considered for inclu-
sion in our rapid review.
Inclusion/Exclusion Criteria
Explicit, research-question-driven eligibility criteria were set
out, informed by the COnsensus-based Standards for the
selection of health Measurement INstruments (COSMIN)
initiative guidelines for the selection of PROMs.19
Inclusion Criteria
Eligible studies were those that: (a) Developed and tested
a PROM (ie, developed with direct patient input and devel-
oped as a self-reportedmeasure) to speciﬁcally assess patients’
medicine burden and/or patients’ experiences with prescribed
(multiple) medicines (either as a whole or in a sub-domain
/subscale). (b) Involved patients experiencing two or more
long-term health conditions (ie, multimorbidity9) and/or
patients receiving multiple medicines (ie, experiencing poly-
pharmacy). (c) Evaluated one or more measurement property
and/or the interpretability (ie, distribution of scores, missing
items, ﬂoor/ceiling effects, change scores) of the PROMunder
development. We also considered studies that tested/devel-
oped revised versions of a pre-existing PROM, and subse-
quently analyzed original and revised PROM versions, on the
proviso that they met all our eligibility criteria.
Exclusion Criteria
We excluded studies that: (a) Were not concerned with
development/testing of a PROM. (b) Developed a PROM
that comprised only individual items on medicine-related
experiences or burden, ie, items did not form a stand-alone
sub-domain/subscale. (c) Used the PROM only to measure
its target outcome(s), eg, observational studies or rando-
mized controlled trials. (d) Used a PROM to validate
another instrument. (e) Developed/tested a PROM in lan-
guages other than English and consequently in cultures
other than those where English is the native language. (f)
Were (systematic) literature reviews.
Screening and Study Selection
We transferred retrieved records onto Endnote® reference
management software (http://endnote.com/), where they
were de-duplicated and subsequently screened on the basis
of title and abstract. Retained records were accessed in full-
text, and further screened against our eligibility criteria.
Data Extraction and Synthesis
We extracted data from the ﬁnal sample of studies onto
a bespoke data extraction form created for this rapid review
and inserted into an Excel spreadsheet for ease of use. The data
extraction was in line with RQs 1 and 2 to generate informa-
tion on PROM content, target PROs and psychometric robust-
ness. All evidence was integrated in a thematic narrative
synthesis that generated summaries of key PROM elements,
content domains and psychometric properties for considera-
tion in Phase 2. A glossary of all psychometric terms used in
this study can be found in Supplementary ﬁle 2.
Consultation with Stakeholders (Phase 2)
To answer RQs 3 to 5, qualitative interviews were con-
ducted with key stakeholders, including members of the
public and healthcare professionals.
Study Design
Descriptive, cross-sectional, qualitative study.
Eligibility and Sampling
Eligible members of the public were: Adult (≥18 years of
age) men and women; Diagnosed with ≥2 long-term health
conditions or caring for a loved one diagnosed with ≥2
long-term health conditions (ie, multimorbidity9); Able to
speak, write and communicate in English; Not diagnosed
with major cognitive or mental disorder that affected
communication.
Dovepress Kotronoulas et al
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Eligible healthcare professionals were: General practi-
tioners, practice pharmacists, elderly care consultants,
advanced nurse practitioners, and care home staff; Involved
in the care of people with multiple chronic illnesses.
Convenience sampling was used as a pragmatic
approach to the study’s tight timelines. We aimed to conduct
up to 20 interviews with members of the public and up to 20
interviews with healthcare professionals to increase the
odds for satisfactory diversity in backgrounds and experi-
ences of study participants.
Procedures
Members of the public were identiﬁed and recruited from
community groups, charitable organizations or public
libraries. We also posted advertisements to Twitter and the
dedicated online platform “Call for Participants” (https://
www.callforparticipants.com/). The researcher ﬁrst checked
eligibility with members of the public interested in the study,
then offered speciﬁc information using a Participant
Information Sheet and Privacy Notice. The researcher
offered to clarify any points and answer possible questions.
Healthcare professionals were recruited via diverse
routes, including Twitter and non-NHS professional meet-
ings and conferences. We also used a snowballing techni-
que whereby healthcare professional participants invited
colleagues via their networks to consider participation. We
sent healthcare professionals interested in taking part
a Participant Information Sheet and Privacy Notice to
their email address. The researcher again offered to clarify
any points and answer possible questions.
Potential participants were free to refuse without
a requirement to justify their decision and without any
penalty. If an eligible member of the public agreed or
healthcare professional wished to take part in the study,
we provided him/her with a consent form to sign and
return, and then agreed a suitable date/time and mode for
the interview. Research participants were free to withdraw
at any point if they so wished without a requirement to
justify their decision.
Data Collection
Sequential, one-to-one, semi-structured interviews were con-
ducted by the lead author or a research assistant. We con-
ducted the interviews in a sequential fashion, depending on
research participants’ earliest availability. We offered diverse
interview modes, ie, face-to-face interviews or telephone/
Skype interviews, in order to facilitate easier recruitment/
data collection. The interview took place at a time (and place
where applicable) most convenient to the research partici-
pant. We anticipated that interviews would be 30–60 mins
long, with a mean duration of 45 mins.
In preparation for the interviews, we used ﬁndings from
the rapid review to construct an interview guide to allow the
systematic exploration of stakeholders’ opinions/views.
Before any given interview, we sent each research partici-
pant a summary sheet to ensure basic understanding of the
concepts of polypharmacy, medicine burden and PROMs,
and key ﬁndings from the rapid evidence review. At the end
of the interview, we debriefed the research participant and
thanked him/her for their time and contribution.
Data Analysis
Thematic content analysis was undertaken.20 Thematic con-
tent analysis is a useful approach for answering questions
about the salient issues for a particular group of respondents
or for identifying typical responses.20 The analysis of tran-
scripts began with familiarization. The lead author identi-
ﬁed themed categories based on the research objectives,
which were subsequently veriﬁed by the co-authors. Using
the three pre-set conceptual categories (experiences with
using medicines, views/opinions about PROMs, and most
meaningful/important PROs) to serve as an initial set of
themes, we established a framework in which these three
overarching themes served as larger elements into which
emerging concepts were categorized as sub-themes.
Results
Rapid Review (Phase 1)
Search Results
After completing the initial identiﬁcation and screening
process, we retained and retrieved in full-text 71 poten-
tially eligible articles. Of these, we excluded 58 for var-
ious reasons (see Figure 1). Thirteen studies met our
eligibility criteria and comprised our ﬁnal sample. These
studies described the development and/or validation of 12
PROMs. Access links to these PROMs can be found in
Supplementary ﬁle 3.
Overview of Identiﬁed PROMs
Three measures were different versions of the Living
with Medicines Questionnaire (LMQ;21,22 LMQ-2;23
LMQ324). Two were different versions of the Treatment
Satisfaction Questionnaire for Medication (TSQM v1;25
TSQM v226). Another two were different versions of the
Patients’ Attitudes Towards Deprescribing (PATD;27
rPATD28).
Kotronoulas et al Dovepress
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The remaining ﬁve were single-version measures,
including the following: Beliefs about Medicines
Questionnaire (BMQ29); Medication Use
Questionnaire (MedUseQ30); Medication-Related
Burden Quality of Life (MRB-QoL31); Patient
Experience with Treatment and Self-Management
(PETS32); and Patient Perceptions of Deprescribing
Questionnaire (PPDQ33).
PRISMA 2009 Flow Diagram
Records identified through 
database searching; n = 2,018 
(Medline; n = 149) 
(CINAHL; n = 382) 
(PsycINFO; n = 179) 
(SocINDEX; n = 193) 
(Web of Science; n = 552) 
(Cochrane Library; n = 294) 
(Google Scholar; n = 269) 
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 Additional records identified 
through other sources: 
(Katusiime et al. 2016; n = 17) 
(Reference lists of full-text 
articles; n= 5) 
Duplicates removed during de-
duplication process (n = 313) 
Records 
screened 
(n = 1,705)
Records excluded 
(n = 1,656) 
Full-text articles assessed 
for eligibility 
(n = 71) 
Full-text articles excluded, 
with reasons 
N=47 articles from database search 
• Not concerned with 
developing/testing an outcome 
measure; n = 8 
• Not concerned with 
developing/testing a PRO measure; n 
= 10 
• PRO measure not measuring 
medicine 
burden/experiences/outcomes; n = 4 
• PRO measure of overall treatment 
burden; n = 2 
• PRO measure not relevant to 
multimorbidity/polypharmacy; n = 3 
• Not in English/English culture; n = 8 
• Literature review; n = 12 
N=11 articles/PRO measures from 
Katusiime et al. 2016 
• No real PRO measure; n = 6 
• PRO measure developed in language 
other than English; n = 3 
• Specific to one organisation for 
auditing purposes; n = 1 
• Overall treatment burden, no 
subscale specific to medicines; n = 1 
Studies included in 
narrative synthesis 
(n = 13) 
Figure 1 PRISMA ﬂow diagram of article screening and selection procedures (adapted from Moher et al, 200917).
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Origin, Population and Setting
Five PROMs were developed in the USA (MedUseQ;30 MS-
PETS;32 PPDQ;33 TSQM v1;25 TSQM v226), four were
developed in the UK (BMQ;29 LMQ;21,22 LMQ-2;23
LMQ324), and three in Australia (PATD;27 rPATD;28 MRB-
QoL31).
The PROMs were developed primarily with chroni-
cally ill adults (>18 years), using one or more long-term
prescribed medicines. Study participants were recruited
from hospitals, community pharmacies, senior housing
facilities or community-based organizations for older
adults, health websites/social media, or the general public.
Statistics about multimorbidity, ie, medians (≥2 con-
current chronic conditions per person), or references to
“patients with multiple chronic conditions” were explicitly
given for the MRB-QoL,31 PATD,27 and MS-PETS.32
Statistics about polypharmacy, ie, rates (40–93.5%) or
medians (≥5 concurrent prescribed medicines per partici-
pant), were explicitly reported for the LMQ-2,23 LMQ3,24
MedUseQ,30 MRB-QoL,31 MS-PETS,32 PPDQ,33 and
rPATD.28 In all other studies, numbers of comorbid con-
ditions per participant and/or of concurrent medicines per
participant were either not reported or fell below the multi-
morbidity/polypharmacy thresholds.
User Involvement
Direct user (patients and clinicians) involvement at both
the “item generation” and “item clariﬁcation” stages took
place for the LMQ,21,22 LMQ-2,23 MedUseQ,30 MS-
PETS,32 PPDQ,33 rPATD,28 and TSQM v1.25
For the BMQ,29 direct user involvement took place at
the “item generation” stage only. For the LMQ3,24 MRB-
QoL,31 PATD,27 and TSQM v2,26 direct user involvement
took place at the “item clariﬁcation” stage only.
User involvement was in the form of focus group or
one-to-one interviews, concept mapping exercises, expert
panels, and cognitive interviews.
Focus Area, Domains and Dimensionality
The PROMs tapped into ﬁve broad areas of focus, namely
medicine burden (LMQ;21,22 LMQ-2;23 LMQ3;24 MRB-
QoL;31 PETS32); attitudes towards deprescribing (PATD;27
rPATD;28 PPDQ33); satisfaction with medicines (TSQM
v1;25 TSQM v226); medicine use problems
(MedUseQ30); and beliefs towards medicines (BMQ29).
Within their areas of focus, nine PROMs targeted
diverse domains (LMQ;21,22 LMQ-2;23 LMQ3;24 MRB-
QoL;31 PETS;32 rPATD;28 PPDQ;33 TSQM v1;25 TSQM
v226). Three PROMs covered only one domain (PATD;27
MedUseQ;30 BMQ29); however, the BMQ29 was divided
into subscales.
In terms of dimensionality, nine PROMs featured
between four and ten subscales LMQ;21,22 LMQ-2;23
LMQ3;24 MRB-QoL;31 rPATD;28 PPDQ;33 TSQM v1;25
TSQM v2;26 BMQ29). The PETS32 is a multi-dimensional
measure of treatment burden comprising nine subscales,
but only the Medicines subscale was relevant to the remit
of this review, and thus speciﬁcally targeted (thereafter,
referred to as MS-PETS32). The MedUseQ30 is
a psychometrically conﬁrmed unidimensional measure,
whereas the PATD27 has no conﬁrmed dimensionality.
Domain Content: Target PROs
Collectively, the PROMs covered 14 unique domains
(Table 1). Owing to the developmental work of the
PROMs involving the direct patient and public involve-
ment, these domains most probably reﬂect most issues that
affect people using regular medicines.
The top-3 domains based on the frequency of coverage
across the PROMs were: Impact on daily living due to
medicine use (including medicine burden); Convenience,
practicalities and/or managing medicines (including sup-
port); and Views, attitudes, beliefs and/or perceptions
about medicines (Table 1). The LMQ3,24 MedUseQ,30
and rPATD28 were the most comprehensive measures,
each covering 10 domains.
Scale Item Range
All PROMs were multi-item, ranging from seven to 43 items
per measure. The only measure with fewer than 10 items was
the MS-PETS.32 Five measures included 11–20 items
(BMQ;29 PATD;27 PPDQ;33 TSQM v1;25 TSQM v226).
Two measures included 21–30 items (MedUseQ;30
rPATD28). Four measures comprised 30+ (MRB-QoL31) or
40+ items (LMQ;21,22 LMQ-2;23 LMQ324).
Response Format and Scoring
Ten measures used a 5-point or 7-point Likert scale for
respondents to indicate agreement/disagreement with
statements (BMQ;29 LMQ;21,22 LMQ-2;23 rPATD;28
PPDQ;33 MRB-QoL;31 TSQM v1;25 TSQM v2;26
LMQ3;24 PATD27). Numerical scales (MedUseQ;30 MS-
PETS;32 TSQM v1;25 TSQM v226), visual analogue scales
(LMQ324), or multiple-choice questions (PATD27) were
used less frequently.
Kotronoulas et al Dovepress
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In terms of scoring, eight PROMs employed one scoring
system (BMQ;29 LMQ;21,22 LMQ-2;23 MedUseQ;30
rPATD;28 MS-PETS;32 PPDQ;33 MRB-QoL31). Four mea-
sures employed two scoring systems (TSQM v1;25 TSQM
v2;26 LMQ3;24 PATD27). Two measures included an open-
ended ﬁeld (LMQ;21,22 MRB-QoL31). For three PROMs
(BMQ;29 LMQ-2;23 LMQ324) both subscale and total
scores can be calculated. Seven PROMs yield subscale
scores only (MRB-QoL;31 MS-PETS;32 rPATD;28
PPDQ;33 LMQ;21,22 TSQM v1;25 TSQM v226). For the
MedUseQ30 a single total score can be calculated, whereas
for the PATD27 no total score can be calculated.
Recall Period
Seven PROMs involve generic items with no speciﬁc
timeframe for recall (BMQ;29 LMQ;21,22 LMQ-2;23
LMQ3;24 PATD;27 rPATD;28 PPDQ33). Recall period for
ﬁve measures ranged from “past 2 weeks” (MRB-QoL31)
to “past 2–3 weeks” (TSQM v1;25 TSQM v226) to “past 4
weeks” (MS-PETS32) to “past 3 months” (MedUseQ30).
Psychometric Robustness
Reliability: Internal Consistency and Stability
Internal consistency was reported for all PROMs except
for the LMQ.21,22 Measurement of this property relied on
the calculation of two sets of metrics: Cronbach’s alpha
and/or inter-item, item-to-total or inter-scale correlations.
Cronbach’s alphas varied widely across subscales of the
same measure or across different measures. Consistently,
the MedUseQ,30 MRB-QoL,31 MS-PETS,32 TSQM v1,25
and TSQM v226 had alphas at or above the 0.80 threshold
for all of their subscales. For the LMQ324 and rPATD,28
Cronbach’s alphas were acceptable (ie. ≥0.80) for most of
their individual subscales.
Stability (or test-retest) was tested only for the BMQ,29
LMQ3,24 PATD,27 and rPATD.28 Investigation included
calculation of parametric/non-parametric correlation coef-
ﬁcients or intraclass correlation coefﬁcients (ICC), percen-
tage agreement, or test–retest mean differences. Retest
intervals ranged from 3 days (PATD27) to one (rPATD28)
or 2 weeks (BMQ,29 LMQ324). Stability metrics were
acceptable (ICC≥0.75; ≥80% agreement; no statistically
signiﬁcant mean differences at retest) for all four
PROMs; however, analyses were based on small sam-
ples (n=~30).
Content Validity
Content validity of the PROMs was established by means of
literature reviews and/or stakeholder input. Development of
the LMQ,21,22 LMQ-223 and TSQM v226 relied solely on
patient and public involvement. For the development of the
BMQ29 and TSQM v1,25 literature reviews were comple-
mented by patient input.
Development of the LMQ3,24 MedUseQ,30 MRB-QoL,31
PETS,32 PATD,27 rPATD,28 and PPDQ33 combined extensive
literature reviews with patient and clinician input from expert
panels and focus groups. For item clariﬁcation, cognitive
interviews (LMQ,21,22 LMQ3,24 MedUseQ,30 PPDQ33) or
pilot trials with patients (PATD,27 rPATD,28 TSQM v125)
were also conducted.
Construct Validity
Construct validity of the PROMs was investigated as part
of scale analysis and/or known-groups validity.
Development of most PROMs employed exploratory
factor analysis techniques for scale analysis (BMQ,29
LMQ,21,22 LMQ-2,23 LMQ3,24 MedUseQ,30 MRB-
QoL,31 PETS,32 PPDQ,33 rPATD,28 TSQM v1,25 TSQM
v226). Conﬁrmatory methods to ascertain underlying con-
tent domains were used less frequently (BMQ,29
LMQ,21,22 LMQ3,24 PETS,32 PPDQ,33 TSQM v226). No
scale analysis was conducted for the PATD.27
Known-groups validity was conﬁrmed via signiﬁcant
between-group differences for six PROMs, namely:
BMQ29 (allopathic v. complementary care group); LMQ-
223 (1–4 v. 5–8 v. ≥9 concurrent medicines); LMQ324
(higher scores for patient groups who took 5+ medicines,
took medicines 3 times daily, required assistance with
taking medicines, paid for prescriptions); MRB-QoL31
(higher scores for patient groups with polypharmacy, mul-
timorbidity, and drug burden index>0); PATD27 (0–5
v. 6–9 v. 10+ medicines); and PETS32 (higher scores for
patient groups with lower health literacy, less adherence to
medicines, and more ﬁnancial difﬁculties). There was con-
ﬂicting evidence reported for the rPATD28 and TSQM
v1.25
Criterion Validity
For most PROMs, criterion validity was established by inves-
tigating either one or both of its two aspects, ie, concurrent
validity (convergent and/or discriminant validity) and predic-
tive validity.
Convergent validity was established for the BMQ,29
LMQ3,24 MRB-QoL,31 PATD,27 rPATD,28 MS-PETS,32
TSQM v1,25 and TSQM v226 via statistically signiﬁcant rela-
tionships of these PROMs with other conceptually similar
Kotronoulas et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Patient Preference and Adherence 2019:132078
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
20
9.
11
5.
97
 o
n 
20
-D
ec
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
measures. Discriminant validity was established only for the
MRB-QoL.31
Concurrent validity was more fully examined for the
MRB-QoL.31 For four PROMs, no evidence on concurrent
validity is available (LMQ,21,22 LMQ-2,23 MedUseQ,30
PPDQ33).
Predictive validity was tested only for three PROMs, ie,
BMQ29 (beliefs about medicines predicted greater adherence
to medicine use), TSQM v125 (satisfaction with medicines
predicted likelihood to discontinue medicines), and TSQM
v226 (satisfaction with medicines predicted medicine persis-
tence/completeness).
Floor/Ceiling Effects
Floor and/or ceiling effects were reported for eight
PROMs. Floor effects were reported for the LMQ324
(ﬁve items affected; ﬂoor effects at max. 59.1%) and
MedUseQ30 (across all items; ﬂoor effects at 9.8%).
Ceiling effects were reported for the LMQ-223 (one item
affected; ceiling effects at 68.5%), TSQM v125 (across
subscales; ceiling effects at 8.9–41.1%, global satisfaction;
ceiling effects at 12.9%), and TSQM v226 (across sub-
scales; ceiling effects at 8.2–76.7%, overall satisfaction;
ceiling effects at 14.3%).
A mix of ﬂoor and ceiling effects were reported for the:
MRB-QoL31 (Social burden subscale; ﬂoor effects at 0.6–-
19%, Therapeutic relationship subscale; ceiling effects at 1.-
7–24.8%); MS-PETS32 (across all items; ﬂoor effects at
38–59%, ceiling effects at 0%; Stand-alone medicines items:
Reliance, ﬂoor effects at 46–65%, ceiling effects at 1–14%;
Side-effects, ﬂoor effects at 53–71%, ceiling effects 1–3%);
and PPDQ33 (unimportance of medicines subscale, ﬂoor
effects at 0.76–6.8%, Provider knowledge subscale, ceiling
effects at 0–12.5%).
Consultation with Stakeholders (Phase 2)
Between May and June 2019, 12 members of the pub-
lic and 11 healthcare professionals expressed interest in
the study. Seven members of the public (RR=58.3%)
and eight healthcare professionals (RR=72.7%) pro-
vided written informed consent and completed an inter-
view. Interviews with members of the public lasted for
a mean of 42.4 mins (22–58 mins); the mean duration
of interviews with healthcare professionals was 30
mins (19–48 mins). Background characteristics of all
participants are shown in Tables 2–4.
We extracted three overarching themes, underpinned
by within-theme sub-themes: Experiences with using
multiple medicines – Emerging PROs (Theme 1);
Relevance, potential uses and handlers of PROMs
(Theme 2); Most meaningful PROs for medicines reviews
(Theme 3). Representative quotes can be found in
Supplementary ﬁle 4.
Table 2 Background Characteristics of the Study Participants
Participant
Group
Variable Attribute Value
Members of
the public
Gender Male:female 3:4
Role Patient:carer 6:1
Age (years) Mean±SD 39.5
±20.3
Median 32
Min-Max 22–78
Family status Married/partnered 2
Single 3
Widowed 2
Employment
status
Employed (full-time) 3
Employed (part-time) 2
Retired 2
Student 1
Chronic
conditions
Median 4
Min-Max 2–6
Prescribed
medicines
Median 7
Min-Max 3–16
Healthcare
professionals
Gender Male:female 6:2
Clinical role General practitioner 3
Consultant 1
Pharmacist 2
Pharmacy technician 1
Advanced nurse
practitioner
1
Clinical
experience
(years)
Mean±SD 22.6
±8.1
Median 25
Min-Max 10–30
Area of practice Urban:rural 5:3
Abbreviation: SD, standard deviation.
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Theme 1: Experiences with Using Multiple
Medicines – Emerging PROs
Within Theme 1, we identiﬁed seven sub-themes that
comprehensively described the self-reported or healthcare
professional-reported experiences of members of the pub-
lic with multiple medicines.
Social Pressure, Embarrassment and Stigma
Members of the public talked about a general sense of
unease, embarrassment and perceived stigma when
managing, taking or talking about medicines in front
of or with others. In certain cases, such feelings were
fueled by societal, cultural or family attitudes towards
medicine use and links with overt or covert pitifulness
due to ill health, or assumptions about mental illness or
addiction.
Navigating the Prescribing System
Collectively, participants shared their concerns or frustra-
tions regarding dealing with a system that seems fragmented
and not synchronized. Members of the public talked about
being under multiple different teams that do not always seem
to communicate well. This kind of separation was perceived
as a “big divide” that only creates confusion about what
services deal with what, particularly in relation to transitions
from primary to secondary care and vice versa.
As a result, patients often feel unable to follow-up
changes in their treatment protocol made from different
prescribers, and particularly worry about shortage or una-
vailability of medicines or dosages in this complex envir-
onment. Participants also talked about “legacy regimens”
that might remain untouched for a long time before they
are reviewed, possible reluctance to change ineffective
regimens for fear of stepping onto other prescribers’ toes,
and prescriptions that might not be reviewed due to sheer
lack of resources.
Multiple Medicines, Side Effects and Interactions: Number
V. Impact
A distinction between number of medicines and impact of
side effects was evident in the interviews. Participants felt
that side effects and/or interactions were not necessarily
linearly related to increasing numbers of medicines. Side
effects and/or interactions (being one of the many layers of
medicine burden) were seen as unique, stressful events
that might be attributed to one or two medicines only,
although which ones exactly among multiple medicines
could be hard to decipher.
Table 3 Breakdown of Characteristics of Members of the Public
Study ID Gender Age
(Years)
Family
Status
Work Status Conditions
(n)
Prescribed Meds
(n)
Interview Duration
(Minutes)
MP-01 Female 24 Single Student 5 5 27
MP-03 Male 22 Single Employed (p/t) 2 3 22
MP-04 Female 29 Partnered Employed (f/t) 3 8 51
MP-06 Female 56 Widowed Retired 5 7 50
MP-08 Male 32 Single Employed (f/t) 3 5 36
MP-10 Male 36 Married Employed (p/t) 6 16 58
MP-12 Female 78 Widowed Retired 4 10 53
Abbreviations: MP, member of the public; p/t, part-time; f/t, full-time.
Table 4 Breakdown of Characteristics of Healthcare Professionals
Study ID Gender Clinical Role Clinical Experience (Years) Area of Practice Interview Duration (Minutes)
HCP-01 Male GP 20 Semi-rural 19
HCP-02 Male GP 30 Urban 24
HCP-03 Male GP 12 Semi-rural 48
HCP-05 Male Consultant geriatrician 28 Urban 28
HCP-06 Female Pharmacist 30 Urban 35
HCP-07 Male Pharmacy technician 10 Rural 20
HCP-08 Female Pharmacist 29 Urban 47
HCP-11 Male ANP 22 Urban 19
Abbreviations: HCP, healthcare professional; GP, general practitioner; ANP, advanced nurse practitioner.
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At the same time, a sense of concern and anticipatory
anxiety about possible side effects and/or interactions was
described, particularly in relation to newly prescribed
medicines. Despite this evident impact, an interesting
viewpoint was shared that some people might be keen to
withstand any side effects in the hope of medicine
effectiveness.
Managing (with) Medicines on a Day-to-Day Basis
Participants dwelled on a range of practicalities related to
managing (with) medicines in everyday life. Taking multi-
ple medicines in one go can “be a pain” and ﬁnding the
“right” form (eg, tablet or capsule) can take a bit of
experimenting. Moreover, dealing with different packs
and bottles and medicines of the same color and shape
can “mix you up”, following instructions for different
medicines can be confusing, and carrying medicines
about can be impractical. Participants also talked about
cases where family members seemed to struggle with the
responsibility of planning and administering medicines
without help. Discussion also revolved around restrictions
and a lack of spontaneity in life that medicines seem to
pose.
The general impression was that adjusting one’s life-
style and socializing can often be a struggle, while arran-
ging holidays and travelling might be compromised unless
well-planned in advance. In terms of planning, one parti-
cipant discussed the likely implications of residential
remoteness to getting access to medicines.
Members of the public also talked about how reducing
the amount of medicines can make a “massive difference”,
and how this might increase their sense of being in control
and their feelings of empowerment. Similarly, little prac-
tical aids, such as the use of dosette boxes, together with
self-conﬁdence and help from the family could increase
concordance to the treatment plan and reduced the risk for
overuse or abuse.
Getting to Know Your Medicines
Members of the public agreed that understanding one’s
own medicines means the healthcare professional takes
the time to consult and provide clear explanation. The
general feeling was that much more must be discussed
about medicines, but that is not always the case, and this
might be seen as people being left to deal with medicines
on their own. One doing their own research (mainly,
online) was another way of getting at least some informa-
tion. In any case, members of the public collectively
voiced a need for better understanding about what medi-
cines do, about the need for those prescribed medicines,
about possible side effects and interactions, and about
timing and mode of administration.
Healthcare professionals also agreed on the require-
ment to adequately educate patients and families to
develop a sense of ownership over their medicines.
Based on their clinical experiences, common issues were
a lack of understanding about: what the prescribed medi-
cines are for; the duration, importance, and risks of not
following the treatment plan; the intended beneﬁt and
effectiveness of a given medicine for the person; the
need for regular medicines reviews; and whether and
why multiple medicines are appropriate or not.
Additional important views revolved around: patients
having set beliefs and opinions about how medicines work
and how they should be used; dealing with people who do
not want to know or be involved in decision-making; and
dosette boxes making people less aware of their own
medicines despite their practical aspects. The potential
link between understanding the effectiveness of a given
medicine and giving up ﬁxed and unhelpful beliefs about
medicines was also discussed; this can subsequently
increase the odds for the patient to follow the treatment
plan and their satisfaction with medicines.
Getting off Medicines
In the interviews, a distinction was made apparent between
patient vs. healthcare professional driven discontinuation.
Members of the public indicated that their wishes to
reduce or stop a medicine should be followed by an honest
discussion with the healthcare professional, and be appro-
priately followed up and monitored.
For healthcare professionals, experienced side effects
and people’s initial acceptance of the treatment plan might
drive people’s desire to reduce medicines. Although not
normally directly raised by patients, if the healthcare pro-
fessional broaches the topic, patients seem open to discuss.
However, it was suggested that, where discontinuation is
healthcare professional driven, providers must ﬁrst build
trust and approach the topic sensitively in order to curb
possible resistance from patients and families concerned
about stopping or changing medicines.
Involvement and Engagement in Decisions About Medicines
Building rapport and relationship, while working in partner-
ship, were key aspects of involving people in decisions about
medicines. Two members of the public were critical towards
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how inclusive some healthcare professionals seem to be
despite a clear appetite for involvement frompatients or family
members.
In their interviews, healthcare professionals agreed that
the top limiting factor is not the patient’s appetite to be
involved, but probably the lack of time in the system to
allow a thorough discussion, or even a screening process
about who wants to be involved and who does not. In any
case, using language acceptable to people (eg, agreement
to plan of treatment instead of adherence or compliance)
and letting people consider how conﬁdent or now they feel
to implement an agreed treatment plan were suggested as
factors promoting engagement.
Theme 2: Relevance, Usability, Usage and Potential
Handlers of PROMs
Four sub-themes were included in Theme 2, describing
various aspects of implementing PROMs in clinical prac-
tice to aid polypharmacy medicines reviews.
Perceived Relevance in Clinical Practice
All participants agreed on the clinical relevance of PROMs
to aid medicines reviews, discussing a wide range of
potential beneﬁts. Members of the public felt that
PROMs could: standardize the consultation; help health-
care professionals gain a deeper understanding of the
patient’s and family’s perspective; act as reminders for
people to raise issues during the consultation; enhance
relationships and communication between patients and
healthcare professionals; and facilitate transfer of informa-
tion to allow better communication across healthcare pro-
fessionals. Moreover, PROMs were facilitators of future
planning; enablers of improved knowledge on the purpose
and actions of medicines; vehicles to legitimize people’s
concerns; and promoters of honesty in people’s reports
about side effects and attempts to discontinue medicines.
Healthcare professionals considered PROMs as
a “good starting point” to help them understand people’s
perceptions, preferences and concerns by asking key ques-
tions; help them communicate the intended beneﬁt of pre-
scribed medicines, thus increasing people’s understanding
of their medicines; and help people to actively engage with
and take ownership over their medicines, thus increasing
their involvement in decision making.
Usability Aspects
Brevity and clarity were the most important usability
aspects of PROMs raised in the interviews. Participants
suggested that implementable PROMs for medicines
reviews must be quick to ﬁll out (in about 5 mins); include
only those essential/meaningful questions; allow people to
expand on their responses; provide the option of paper or
electronic version; be user-friendly, easily understood and
not too wordy; and take health literacy into account.
Delivery, Timing and Frequency
Regarding usage of PROMs, participants’ suggestions ran-
ged widely from weekly to at least once a year. Five
members of the public favored a monthly administration.
For others, delivery of PROMs could be tied to changes to
the treatment plan, introduction of a new medicine, or
follow up after problems experienced with a given medi-
cine. One participant suggested that copies of PROMs be
available at the surgery or pharmacy or online to allow
prompt reporting. What was felt as particularly important
was that PRO information be made available to all health-
care professionals involved in one’s treatment plan.
Healthcare professionals endorsed an on-going process of
collecting PROMs. They also favored a delivery mode were
PROMs are ﬁlled out beforehand prior to the consultation to
allow people to do some homework and healthcare profes-
sionals to prepare. A sensitive approach and one that ensures
anonymity was also suggested to foster honesty in people’s
responses. To enable uptake of PROMs a buy-in process for
patients and healthcare professionals would need to take
place, whereby patients can easily understand the purpose
of the PROMs, while healthcare professionals are supported
to counterbalance the volume of information gleaned with
the time available to review.
Potential Handlers of PRO Information
Among participants, pharmacists (particularly, community
pharmacists) were considered as most appropriate to dis-
tribute, collect and review PROMs for medicines reviews.
A role for nurses and GPs was also suggested. However, the
general consensus was that, regardless of who is involved,
the process must be properly and carefully planned.
Theme 3: Most Meaningful PROs for Medicines
Reviews
Within Theme 3, we identiﬁed four sub-themes that
described the most meaningful PROs to be assessed in
medicines reviews (Figure 2).
Knowledge, Information and Communication About Own
Medicines
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Knowledge about one’s own medicines, understanding the
intended beneﬁt of medicines, obtaining information and
communicating about own medicines were considered the
most important and meaningful PROs to be assessed dur-
ing medicines reviews. Participants justiﬁed their views by
raising points around the need to: Help people understand
what medicines they take, what they are for, what they do,
what the intended beneﬁt is, and how to self-manage;
Understand the need for more information and people’s
appetite for more information, while assessing any residual
uncertainty; Have access trustworthy information about
medicines; Ensure that the patient understands and is
happy to follow the treatment plan; and Promote effective
communication between patients/carers and healthcare
professionals, and among providers and services.
Perceptions, Views and Attitudes About (Own) Medicines
Perceptions and concerns about the appropriateness and effec-
tiveness of prescribed medicines, including understanding
people’s personal goals and satisfaction with prescribed med-
icines were key PROs to be assessed in medicines reviews.
Participants talked about perceptions, views, goals and
attitudes that, albeit important, are often undervalued or
overlooked. A need for open conversations was indicated,
where people can express whether they perceive beneﬁt
from their medicines, what they expect and want to
achieve, how appropriate they deem their treatment plan,
and what unhelpful personal, family or societal views and
beliefs about medicines might interfere with the concor-
dance of the treatment plan.
Impact on Daily Living: Side Effects and Practicalities
Impact on daily living was considered from a dual view-
point, the triggers being experiences of side effects and the
practicalities of managing medicines (eg, ﬁtting taking
medicines into work/life schedule, availability and acces-
sibility of medicines, or knowing who to report problems
and how to reach them).
Participants felt strongly about the need to assess both
of these sources of distress, any underlying factors (eg,
lack of self-conﬁdence or sense of control), as well as their
implications for both patients and family members/carers,
including ill health, impact on concordance of plan, impact
on work and/or lifestyle.
Medicine Usage: “As Planned” Use, Misuse, Abuse, No
Use
Members of the public and healthcare professionals
equally expressed that monitoring and follow up (includ-
ing issues around concordance, misuse, abuse and discon-
tinuation) would be important to be included in PRO
assessments during medicines reviews. The general view
was that assessment of such PROs could help optimize the
treatment plan as necessary, while considering the extent
to which knowledge, perceptions or impact on daily living
might play a role.
Discussion
In this study, we identiﬁed four core categories of most
meaningful PROs to be assessed in polypharmacy med-
icines reviews (Figure 2), and 12 validated PROMs that,
to different extents, can facilitate the assessment of the
core PROs (Table 1). Diversity in our participants’
demographic and clinical or professional characteristics
catered for a rich description of experiences of using
multiple medicines in Phase 2, which underpin evidence
already reported in the literature.7,11,12 At the same time,
our data directly linked to the 14 content domains
extracted during the rapid review of PROMs in Phase
1. In line with previous evidence,34 members of the
public described a multifaceted experience of managing
and living with multiple medicines that was summarized
in seven sub-themes. Healthcare professionals concurred
with these views, except for the perceived
Perceptions, 
views, attitudes
Effectiveness & 
appropriateness of 
(own) meds
Personal, family,  
societal
Impact on   
daily living
Side effects & 
practicalities
Medicine  
usage
“As planned” use, 
misuse, abuse, no use
Knowledge, 
information & 
communication
About own meds
Figure 2 Thematic core categories of most meaningful/important PROs for assess-
ment during polypharmacy medicines reviews.
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embarrassment and stigma related to medicine use.
These concepts have been previously investigated
among people with mental health illnesses,35 and might
be more prevalent among users of psychiatric
medicines.36
An overall need was expressed for easier navigation of
the prescribing system, improved patient/family knowl-
edge about the purposes and beneﬁts of prescribed medi-
cines, increased attention to the impact of medicines on
daily living, and better collaboration and communication
between patients/families and healthcare professionals,
and across providers and services.
Effective use of PROMs was seen as conducive to
addressing these needs. All participants agreed on the
clinical relevance of PROMs, providing a rich account of
justiﬁcations. In parallel, a good range of suggestions was
made around usability and usage of PROMs to enhance
integration and uptake in clinical practice. The consensus
was that an effective buy-in process must involve:
● Consultation to identify best ways to introduce
PROMs in clinical practice and best handlers of
PRO information;
● A clear purpose for collecting PROMs;
● Realistic and ongoing collection at key time-points;
● PROMs that are easy to understand and not too long
nor too wordy; and
● PROMs that only include key/essential and mean-
ingful questions.
In relation to the latter point, participants identiﬁed a core
set of four most meaningful PROs to be assessed in poly-
pharmacy medicines reviews (Figure 2). Participants even
went on to dwell about the potential interactions among
these PROs, eg, how knowledge might interact with per-
ceptions to affect usage, how impact on daily living can
affect usage and vice versa, or how knowledge and com-
munication can affect the degree of impact on daily living.
Participants collectively agreed that assessment of these
four core PRO areas during medicines reviews can lead to
focused and meaningful conversations, actions and interven-
tions to tackle problematic polypharmacy (particularly in
areas akin to prescription of psychiatric medicines and the
associated health risks37,38), increase health literacy, optimize
the treatment plan, and enable shared decision making and
agreement to the prescribed (and optimized) treatment plan.
In terms of PROMs, in Phase 1, we searched the literature
looking speciﬁcally for measures developed with direct user
involvement. This was to increase our conﬁdence in their
clarity and relevance to future users in clinical practice. At
the same time, we evaluated such aspects as length, compre-
hensiveness, and psychometric robustness of all measures.
This was to shortlist measures, whose integration in clinical
practice might be more feasible, as well as those that can
return complete, valid and reliable information. To this end,
we considered both single-domain and multi-domain mea-
sures. This was to examine the possibility for individual
psychometrically robust domains to be used as stand-alone
should a bespoke measure be required to be developed for
clinical use out of individual domains of different existing
PROMs.
At face value, PROMs varied widely in terms of length,
comprehensiveness and psychometric robustness. Content
validity through extensive literature reviews and direct and
extensive user involvement at both item generation and clar-
iﬁcation was established for the MedUseQ,30 PPDQ,33 and
rPATD.28 In terms of likely feasibility for clinical use, the
shortest measure was the MS-PETS32 (<10 items) followed
by the BMQ,29 PATD,27 PPDQ,33 TSQM v1,25 TSQM v226
(all at 11–20 items). The most comprehensive measures
(LMQ3,24 MedUseQ,30 and rPATD28) tended to be lengthier,
which could pose a barrier to their feasibility for clinical use.
Even so, none of them covered all 14 of the content domains
identiﬁed from the rapid review (see Table 1), or the four core
thematic categories that were identiﬁed from the qualitative
analysis of interview data.
Reliability and/or validity was fully established only for
some PROMs, but no single PROM was fully validated
across all of these parameters. Reliability (ie, internal con-
sistency and stability) was fully established for the LMQ324
and rPATD28 only. Construct validity was fully established
for the BMQ,29 LMQ3,24 and PETS32 only. Criterion valid-
ity was fully established for the MRB-QoL,31 followed by
BMQ,29 TSQM v1,25 and TSQM v2.26 Across PROMs
where an analysis for ﬂoor/ceiling effects was conducted,
the MedUseQ30 was affected the least.
Practice Implications
All evidence considered, we recommend use of a bespoke
PROM for clinical use, combining psychometrically
robust existing PROMs or domains across existing
PROMs (taking into consideration permission and copy-
right). To make it feasible for use in clinical practice, the
bespoke PROM must be comprehensive enough to address
all four core PRO areas, but not too long, ideally
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incorporating a maximum of 10–15 items with 3–4 items
per core PRO area.39
Use of the bespoke PROM can follow a ﬁve-step pro-
cess to ensure realistic integration in polypharmacy medi-
cines reviews (Table 5). Moreover, to address concerns
raised in this project about the disjointed healthcare system
and lack of coherent communication ﬂow across teams,
disciplines, and settings we recommend further ongoing
consultation to: (a) Identify appropriate timing and time-
points for collection of PRO information, eg, ﬁxed time-
points at monthly intervals or every 6–12 months and/or on
a “as and when” basis, eg, during initial prescription or
when a change to the treatment plan is made. (b) Consider
delivery mode of the bespoke PROM in different formats
(paper or online), availability (in practice surgery, pharmacy
or online, with one copy made available to the reporting
patient or family), and healthcare professionals best placed
to collect (ideally, everyone involved in the patient’s treat-
ment plan) and handle PRO information. (c) Explore-
enhanced real-time and cross-discipline/setting
communication about prescribed medicines via an integra-
tive online platform (or plug-in) that enables integration of
PRO information into the patient’s medical record and
makes PRO information and prescription decisions/changes
(perhaps via use of a ﬂags system) available to all health-
care professionals involved in a patient’s treatment.
Strengths and Limitations
In Phase 1, we followed a rigorous systematic approach to
identify and select all studies that met our eligibility cri-
teria, and synthesize evidence according to PRISMA
guidelines17 and current guidance for rapid reviews.18
We conducted our synthesis of evidence in an unbiased
manner to promote reproducibility. Some limitations of
our sample of studies and review methodology must be
acknowledged. We opted for an inclusive search strategy,
but this was not exhaustive as it was limited to the most
common databases. To abide by the timelines of a rapid
review, we relied on the ﬁndings of a previous systematic
review8 for the period before January 2015. As such, our
ﬁndings might be inﬂuenced by the methodological limita-
tions of that systematic review; however, the extent of this
is only minimal given the methodological rigor of that
systematic review. We further limited our search to
English language publications only. We cannot rule out
the possibility that PROMs published in languages other
than English might have been missed, but we anticipate
that the number of these to be minimal.
In Phase 2, we opted for an inclusive recruitment
strategy to increase diversity in our sample, which to
a certain extent was achieved. Clear description of the
context combined with a detailed account of participant
characteristics enhances the transferability of our ﬁndings
across NHS Scotland. Interviewers had no personal, clin-
ical or professional relationship with the participants,
which enhances the credibility of our data. However, spe-
ciﬁc limitations warrant comment. Due to time constraints,
we opted for a convenience rather purposive sampling,
which in conjunction to a small sample size, may limit
the representativeness of experiences described in our
sample. Speciﬁcally, our ﬁndings seem to be more skewed
towards people already having positive views towards
PROMs, patients rather than family members/carers, and
GPs and pharmacists than registered nurses or medical
consultants. However, our interviews did yield rather rich
datasets with good variability of experiences, which was
also conﬁrmed by mapping ﬁndings to the 14 content
domains of PROMs identiﬁed in Phase 1.
Table 5 Five-Step Process for the Use of a Bespoke PROM for
Realistic Integration in Polypharmacy Medicines Reviews
Steps Description
Step 1 (clinical
relevance)
Consider existing PROMs that have been
fully validated in terms of their content
validity (extensive literature review and
direct user involvement), including user
involvement at the generation and
clariﬁcation stage (ie,
MedUseQ,30 rPATD28 and PPDQ33).
Step 2 (usability) Consider how appropriate the length of
the measures identiﬁed in Step 1 is.
Step 3 (breadth) Consider the content domains that each of
the measures addresses, identifying
overlapping domains and domains that the
measures make a unique contribution to,
so that all four core PROs (and ideally all
14 content domains) can be assessed by
the bespoke PROM.
Step 4 (degree of
established validity)
Consider the extent of construct and
criterion validity undertaken for the
measures identiﬁed in Step 1. Identify valid
stand-alone content domains of individual
PROMs.
Step 5 (content
validity)
Develop draft bespoke PROM and initiate
consultation with stakeholders to establish
content validity in the ﬁrst instance.
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Conclusion
All evidence considered, it is sensible to suggest com-
bining psychometrically robust PROMs or domains
across PROMs into a bespoke PROM that addresses
the four core PROs of the multifaceted experience of
polypharmacy in a comprehensive, yet succinct, way.
A pragmatic approach to the clinical integration of
a PROM (within NHS Scotland and beyond) will be
essential to increase its uptake by healthcare teams and
aid towards identiﬁcation of medicine safety issues,
prevention of inappropriate polypharmacy, and persona-
lization of the treatment plan according to patients’ and
family members’ and carers’ changing needs and
expectations.
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